NEW DELHI, September 23, 2015 /PRNewswire/ --
IO-125: A Novel Supramolecular Platinum Chemotherapy Being Developed in Triple-Negative Breast Cancer
Invictus Oncology Private Limited, a leader in Supramolecular Therapeutics in Oncology, today announced the presentation of pre-clinical results of their lead molecule, IO-125, at ASCO 2015 Breast Cancer Symposium, being held in San Francisco, CA (abstract number 155134). IO-125 is a novel platinum-based supramolecular therapeutic and is being developed in triple-negative breast cancer. The results will be shared at the poster presentation (Saturday, September 26 - two poster sessions scheduled at 11:50 AM PST and 4:45 PM PST). It can also be viewed on the ASCO website, www.asco.org.
Triple-negative breast cancer (TNBC) accounts for 15-20% of all breast cancers and is associated with a poor prognosis, with a median survival of 13 months. There are limited treatment options for this disease. Recent studies have indicated clinical benefits of platinum agents in TNBC.
Scientists at Invictus Oncology designed IO-125 for superior anti-tumor activity by discovering a novel highly active platinum agent and then utilized their supramolecular platform to enhance its biodistribution to tumors vs. normal tissues. The results show that IO-125 has remarkable and sustained activity in TNBC xenograft models. Based on these observations, IO-125 has entered late stages of pre-clincal development.
About Invictus Oncology Private Limited
Invictus Oncology is a privately held company dedicated towards providing cancer patients a better quality of life by developing new generation cancer drugs with better efficacy and less toxicity. A breakthrough discovery involving the use of supramolecular-based strategies to destroy cancer cells, led to the conception of Invictus Oncology. The company was founded in 2011, and is based in New Delhi. With an outstanding team of internationally acclaimed scientists and ground-breaking science, Invictus Oncology is poised to bring the first novel anti-cancer drugs that have been developed in India for global impact.
SOURCE Invictus Oncology Private Limited